Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RA-18C3 · 2 trials · 2 indications
Incidence and type of adverse clinical events
| Arm | Type | Description |
|---|---|---|
| RA-18C3 | EXPERIMENTAL | - |
| Single group | OTHER | - |
| Name | Type | Description |
|---|---|---|
| RA-18C3 | DRUG | For subjects weighing 27-53 kg: 100 mg (1 ml) administered every three weeks by subcutaneous injection. For subjects weighing \> 53 kg: 200 mg (2 ml) administered every three weeks by subcutaneous injection. |
Inclusion Criteria: 1. Age: ≥ 18 2. Moderate to moderately severe inflammatory acne vulgaris: * Investigator's Global Assessment grade of ≥ 3 and, * ≥ 15 inflammatory lesions (no more than 6 nodules) and, * ≥ 15 non-inflammatory lesions 3. Four week washout period for topical and oral ant...
RA-18C3 is an investigational small molecule being developed for dermatology conditions, specifically moderate to severe psoriasis and moderate to severe acne vulgaris. It is currently in Phase 2 clinical development and is not yet approved by the FDA.
RA-18C3 is being developed by Johnson & Johnson, a company publicly traded under the ticker JNJ. The drug is in Phase 2 clinical trials for dermatology indications.
RA-18C3 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. Clinical trials for the drug have been completed, with no active trials currently ongoing.
RA-18C3 has completed two Phase 2 trials: NCT01384630 in moderate to severe psoriasis with 8 participants, and NCT01474798 in moderate to severe acne vulgaris with 11 participants. Both trials were conducted in the United States.
RA-18C3 is a distinct investigational compound with no alternative names listed. It is a small molecule being studied for psoriasis and acne vulgaris, and is not the same as any other approved or investigational drug mentioned.